Table 1– Baseline characteristics of the included patient population at initiation of infliximab therapy
Subjects n47
Male26 (55)
Caucasian36 (77)
Age at initiation of infliximab therapy years48 (28–71)
Disease duration at initiation of infliximab therapy years6.3±7.8
Biopsy-proven sarcoidosis44 (94)
Smoking status#
 Never-smokers25 (58)
 Current smokers7 (16)
 Former smokers11 (26)
Scadding stage
 03 (6)
 I5 (11)
 II16 (34)
 III10 (21)
 IV13 (28)
Extrapulmonary involvement41 (87)
Main treatment indication
 Lungs30 (64)
 Heart2 (4)
 Eye5 (11)
 Central nervous system3 (6)
 Small fibre neuropathy5 (11)
 Spleen1 (2)
 Ear1 (2)
Medication use prior to initiation of infliximab
 Corticosteroids10 (21)
 Immunomodulation3 (6)
 Corticosteroids and immunomodulation33 (70)
 None1 (2)
Concomitant medication
 None3 (7)
 Corticosteroids13 (28)
 Immunomodulation19 (41)
 Corticosteroid and immunomodulation11 (24)
Duration of infliximab treatment months8.5±5.8
Disease activity measurements
 SUVmax lung parenchyma+4.8±4.1
 SUVmax mediastinum+5.5±4.3
 Angiotensin-converting enzyme U·L−172.2±42.4
 Soluble IL-2 receptor pg·mL−15649±5020
 Vital capacity %84.7±19.1
 FEV1 %74.8±22.2
 Diffusing capacity of the lung for carbon monoxide§ %67.1±17.1
  • Data are presented as n (%), mean (range) or mean±sd, unless otherwise stated. SUVmax: maximum standardised uptake value; IL: interleukin; FEV1: forced expiratory volume in 1 s. #: n=43; : n=46; +: n=42; §: n=41.